Quidel Corp (QDEL) 21.05 $QDEL
25.9% Return Seen to Date on SmarTrend Quidel Call (QDEL)
Comtex SmarTrend(R) - Wed May 07, 4:44PM CDT
SmarTrend identified a Downtrend for Quidel (NASDAQ:QDEL) on February 3rd, 2014 at $28.70. In approximately 3 months, Quidel has returned 25.91% as of today's recent price of $21.26.
Jim Cramer's 'Mad Money' Recap: Unsafe at Any Price
at The Street - Thu May 01, 7:00PM CDT
Big money managers are once again shifting direction, Cramer says.
'Mad Money' Lightning Round: Buy, Buy, Buy Gilead Sciences
at The Street - Fri May 02, 5:00AM CDT
Cramer says don't buy Ensco International and Quidel, beware of Gogo but buy more Boeing.
Quidel to Present at Bank of America Merrill Lynch 2014 Health Care Conference
Marketwire - Tue Apr 29, 5:59PM CDT
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic systems, announced today that it will present at the Bank of America Merrill Lynch 2014 Health Care Conference to be held at the Encore at Wynn hotel in Las Vegas, Nevada on Tuesday, May 13, 2014.
Investors are betting against Quidel (QDEL), Should You? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 8:28AM CDT
Investors are betting against Quidel (QDEL), Should You?
Agios Pharmaceuticals (AGIO) Crumbles: Stock Falls by 6.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 7:49AM CDT
Agios Pharmaceuticals, Inc. (AGIO) saw a big move last session, reversing the recent trend for AGIO as the stock is now up around 16.0% in the past one-month time frame.
Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 24, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Quidel declares net loss of USD1.5m for Q1 2014
M2 - Thu Apr 24, 7:15AM CDT
Diagnostic testing company Quidel (NASDAQ:QDEL) on Wednesday reported a net loss of USD1.5m (USD0.04 per share) for the first quarter ended 31 March 2014.
Quidel Reports First Quarter 2014 Financial Results
Marketwire - Wed Apr 23, 3:06PM CDT
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first quarter ended March 31, 2014.
Quidel Has Returned 16.3% Since SmarTrend Recommendation (QDEL)
Comtex SmarTrend(R) - Wed Apr 23, 9:43AM CDT
SmarTrend identified a Downtrend for Quidel (NASDAQ:QDEL) on February 3rd, 2014 at $28.70. In approximately 3 months, Quidel has returned 16.33% as of today's recent price of $24.01.
Quidel passes FDA clearance to market its Lyra Molecular PCR Assay for detection of Pyogenic Streptococcus Group A and C or G bacteria
M2 - Wed Apr 23, 4:18AM CDT
Diagnostic testing company Quidel (NASDAQ:QDEL) disclosed on Tuesday that it has received clearance from the US Food and Drug Administration (FDA) to market its Lyra Direct Strep Assay.
Quidel Receives FDA Clearance for Its Lyra(TM) Molecular PCR Assay for the Detection of Infections From Pyogenic Streptococcus Group A and C or G
Marketwire - Tue Apr 22, 1:30PM CDT
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received clearance, via the De Novo Request process, from the United States Food and Drug Administration (FDA) to market its Lyra Direct Strep Assay, a multiplex real-time PCR assay. This new molecular test detects and differentiates between pyogenic Group A and pyogenic C or G Streptococcal throat infections.
Shares of QDEL Down 14.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Apr 16, 9:16AM CDT
SmarTrend identified a Downtrend for Quidel (NASDAQ:QDEL) on February 3rd, 2014 at $28.70. In approximately 2 months, Quidel has returned 14.62% as of today's recent price of $24.50.
Quidel to Hold First Quarter 2014 Financial Results Conference Call on April 23, 2014
Marketwire - Tue Apr 15, 3:06PM CDT
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will release first quarter 2014 financial results after market close on Wednesday, April 23, 2014.
Quidel Receives FDA Clearance for Its AmpliVue(R) Hand-Held Molecular Diagnostic Test for Herpes Simplex Virus Types 1 and 2
Marketwire - Thu Mar 27, 3:05PM CDT
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the sale of its AmpliVue HSV 1+2 Assay for the differentiation and detection of herpes simplex viruses 1 and 2.
Commit To Buy Quidel Corp. At $22.50, Earn 6.8% Annualized Using Options
at The Street - Wed Mar 12, 10:53AM CDT
Investors considering a purchase of Quidel Corp. stock, but tentative about paying the going market price of $28.57/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Quidel to Present at Cowen 34th Annual Health Care Conference
Marketwire - Tue Feb 18, 4:30PM CST
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the Cowen and Company 34th Annual Health Care Conference to be held at the Boston Marriott Copley Place hotel in Boston, Massachusetts on Monday, March 3, 2014.
25.9% Return Seen to Date on SmarTrend Quidel Call (QDEL)
Comtex SmarTrend(R) - Wed May 07, 4:44PM CDT
SmarTrend identified a Downtrend for Quidel (NASDAQ:QDEL) on February 3rd, 2014 at $28.70. In approximately 3 months, Quidel has returned 25.91% as of today's recent price of $21.26.
Jim Cramer's 'Mad Money' Recap: Unsafe at Any Price
at The Street - Thu May 01, 7:00PM CDT
Big money managers are once again shifting direction, Cramer says.
'Mad Money' Lightning Round: Buy, Buy, Buy Gilead Sciences
at The Street - Fri May 02, 5:00AM CDT
Cramer says don't buy Ensco International and Quidel, beware of Gogo but buy more Boeing.
Quidel to Present at Bank of America Merrill Lynch 2014 Health Care Conference
Marketwire - Tue Apr 29, 5:59PM CDT
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic systems, announced today that it will present at the Bank of America Merrill Lynch 2014 Health Care Conference to be held at the Encore at Wynn hotel in Las Vegas, Nevada on Tuesday, May 13, 2014.
Investors are betting against Quidel (QDEL), Should You? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 8:28AM CDT
Investors are betting against Quidel (QDEL), Should You?
Agios Pharmaceuticals (AGIO) Crumbles: Stock Falls by 6.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 7:49AM CDT
Agios Pharmaceuticals, Inc. (AGIO) saw a big move last session, reversing the recent trend for AGIO as the stock is now up around 16.0% in the past one-month time frame.
Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 24, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Quidel declares net loss of USD1.5m for Q1 2014
M2 - Thu Apr 24, 7:15AM CDT
Diagnostic testing company Quidel (NASDAQ:QDEL) on Wednesday reported a net loss of USD1.5m (USD0.04 per share) for the first quarter ended 31 March 2014.
Quidel Reports First Quarter 2014 Financial Results
Marketwire - Wed Apr 23, 3:06PM CDT
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first quarter ended March 31, 2014.
Quidel Has Returned 16.3% Since SmarTrend Recommendation (QDEL)
Comtex SmarTrend(R) - Wed Apr 23, 9:43AM CDT
SmarTrend identified a Downtrend for Quidel (NASDAQ:QDEL) on February 3rd, 2014 at $28.70. In approximately 3 months, Quidel has returned 16.33% as of today's recent price of $24.01.
Quidel passes FDA clearance to market its Lyra Molecular PCR Assay for detection of Pyogenic Streptococcus Group A and C or G bacteria
M2 - Wed Apr 23, 4:18AM CDT
Diagnostic testing company Quidel (NASDAQ:QDEL) disclosed on Tuesday that it has received clearance from the US Food and Drug Administration (FDA) to market its Lyra Direct Strep Assay.
Quidel Receives FDA Clearance for Its Lyra(TM) Molecular PCR Assay for the Detection of Infections From Pyogenic Streptococcus Group A and C or G
Marketwire - Tue Apr 22, 1:30PM CDT
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received clearance, via the De Novo Request process, from the United States Food and Drug Administration (FDA) to market its Lyra Direct Strep Assay, a multiplex real-time PCR assay. This new molecular test detects and differentiates between pyogenic Group A and pyogenic C or G Streptococcal throat infections.
Shares of QDEL Down 14.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Apr 16, 9:16AM CDT
SmarTrend identified a Downtrend for Quidel (NASDAQ:QDEL) on February 3rd, 2014 at $28.70. In approximately 2 months, Quidel has returned 14.62% as of today's recent price of $24.50.
Quidel to Hold First Quarter 2014 Financial Results Conference Call on April 23, 2014
Marketwire - Tue Apr 15, 3:06PM CDT
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will release first quarter 2014 financial results after market close on Wednesday, April 23, 2014.
Quidel Receives FDA Clearance for Its AmpliVue(R) Hand-Held Molecular Diagnostic Test for Herpes Simplex Virus Types 1 and 2
Marketwire - Thu Mar 27, 3:05PM CDT
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the sale of its AmpliVue HSV 1+2 Assay for the differentiation and detection of herpes simplex viruses 1 and 2.
Commit To Buy Quidel Corp. At $22.50, Earn 6.8% Annualized Using Options
at The Street - Wed Mar 12, 10:53AM CDT
Investors considering a purchase of Quidel Corp. stock, but tentative about paying the going market price of $28.57/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Quidel to Present at Cowen 34th Annual Health Care Conference
Marketwire - Tue Feb 18, 4:30PM CST
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the Cowen and Company 34th Annual Health Care Conference to be held at the Boston Marriott Copley Place hotel in Boston, Massachusetts on Monday, March 3, 2014.
